Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 120-124

  Hirano, Kumi ^a   Naito, Takafumi ^a   Mino, Yasuaki ^a   Takayama, Tatsuya ^a   Ozono, Seiichiro ^a   Kawakami, Junichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemiluminescent immunoassay; Cross reactivity; CYP3A5; Kidney transplantation; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTOCHROME P450 3A5; NITROGEN; PREDNISOLONE; PROGRAF CAPSULE; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSS REACTION; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY DONOR; KIDNEY GRAFT; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; METABOLIC CAPACITY; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; BLOOD; CHEMISTRY; GENETICS; IMMUNOASSAY; KIDNEY TRANSPLANTATION; LUMINESCENCE; METABOLISM;

ADULT; CROSS REACTIONS; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 84866490424     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.07.018     Document Type: Article

References (27)

1. Webster, A.C., Woodroffe, R.C., Taylor, R.S., Chapman, J.R., Craig, J.C., Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ, 331, 2005, 810.
2. Margreiter, R., Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359 (2002), 741–746.
3. Sperschneider, H., A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. Transplant Proc 33 (2001), 1279–1281.
4. Ekberg, H., Tedesco-Silva, H., Demirbas, A., Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007), 2562–2575.
5. Wallemacq, P., Armstrong, V.W., Brunet, M., et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit 31 (2009), 139–152.
6. Iwasaki, K., Shiraga, T., Matsuda, H., Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 42 (1996), 1426–1432.
7. Iwasaki, K., Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22 (2007), 328–335.
8. Kuehl, P., Zhang, J., Lin, Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001), 383–391.
9. Hesselink, D.A., van Schaik, R.H., van der Heiden, I.P., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003), 245–254.
10. Zheng, H., Webber, S., Zeevi, A., et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3 (2003), 477–483.
11. Haufroid, V., Mourad, M., Van Kerckhove, V., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004), 147–154.
12. Kahan, B.D., Keown, P., Levy, G.A., Johnston, A., Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 24 (2002), 330–350.
13. Marubashi, S., Nagano, H., Kobayashi, S., et al. Evaluation of a new immunoassay for therapeutic drug monitoring of tacrolimus in adult liver transplant recipients. J Clin Pharmacol 50 (2010), 705–709.
14. Bazin, C., Guinedor, A., Barau, C., et al. Evaluation of the Architect tacrolimus assay in kidney, liver, and heart transplant recipients. J Pharm Biomed Anal 53 (2010), 997–1002.
15. Hirano, K., Maruyama, S., Mino, Y., Naito, T., Kawakami, J., Suitability of chemiluminescent enzyme immunoassay for the measurement of blood tacrolimus concentrations in rheumatoid arthritis. Clin Biochem 44 (2011), 397–402.
16. Fukuen, S., Fukuda, T., Maune, H., et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12 (2002), 331–334.
17. Bland, J.M., Altman, D.G., Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986), 307–310.
18. Kamdem, L.K., Streit, F., Zanger, U.M., et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51 (2005), 1374–1381.
19. Gonschior, A.K., Christians, U., Winkler, M., Linck, A., Baumann, J., Sewing, K.F., Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem 42 (1996), 1426–1432.
20. Shimomura, M., Masuda, S., Goto, M., et al. Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. Drug Metab Pharmacokinet 23 (2008), 313–317.
21. Venkataramanan, R., Zang, S., Gayowski, T., Singh, N., Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 46 (2002), 3091–3093.
22. Hebert, M.F., Fisher, R.M., Marsh, C.L., Dressler, D., Bekersky, I., Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39 (1999), 91–96.
23. Anglicheau, D., Flamant, M., Schlageter, M.H., et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18 (2003), 2409–2414.
24. Barceló Martín, B., Marquet, P., Ferrer, J.M., et al. Rheumatoid factor interference in a tacrolimus immunoassay. Ther Drug Monit 31 (2009), 743–745.
25. Furst, D.E., Saag, K., Fleischmann, M.R., et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 46 (2002), 2020–2028.
26. Asamiya, Y., Uchida, K., Otsubo, S., Takei, T., Nitta, K., Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin Pract 113 (2009), c330–c336.
27. Ogata, H., Matsui, T., Nakamura, M., Takazoe, M., Suzuki, Y., Hibi, T., A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55 (2006), 1255–1262.